ArticleFrontiers in oncology2025

Cost-effectiveness of companion BRCA testing and adjuvant olaparib treatment in patients with BRCA-mutated high-risk HER2-negative early breast cancer.

Silviya Nikolova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.